AP
JANX icon

Antipodes Partners’s Janux Therapeutics JANX Stock Holding History

Antipodes Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-720
Closed -$9.94K – 139
2025
Q4 		$9.94K Sell
720
-624
-46% -$14.7K ﹤0.01% 129
2025
Q3 		$32.9K Buy
1,344
+296
+28% +$7.21K ﹤0.01% 105
2025
Q2 		$24.2K Buy
1,048
+416
+66% +$11K ﹤0.01% 97
2025
Q1 		$17.1K Buy
+632
New +$23.8K ﹤0.01% 98

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Antipodes Partners's JANX Position: Q1 2026 in Review

Antipodes Partners sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 720 shares — an estimated $9.94K sold.

Antipodes Partners first reported a position in JANX in Q1 2025 and held it in 4 quarters. The position peaked at $32.9K in Q3 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Antipodes Partners reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Antipodes Partners sold 720 Janux Therapeutics shares in Q1 2026, an estimated $9.94K.
  • Antipodes Partners first reported a position in Janux Therapeutics in Q1 2025 and held it in 4 quarters.
  • Antipodes Partners's Janux Therapeutics position peaked at $32.9K in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.